Boc-Phe-Glu(CH2Br)(CH2Br)-OH | 815619-11-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-Phe-Glu(CH2Br)(CH2Br)-OH
• 英文别名: (2S)-6-bromo-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]-5-oxohexanoic acid
• CAS: 815619-11-5
• 化学式: C₂₀H₂₇BrN₂O₆
• 分子量: 471.348
• InChiKey: OHOIDBXPKPPYLM-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  二甲基硫 、 Boc-Phe-Glu(CH2Br)(CH2Br)-OH 以 甲醇 为溶剂， 反应 48.0h， 生成 [(5S)-5-carboxy-5-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]-2-oxopentyl]-dimethylsulfanium;bromide
  参考文献：
  名称：

  Synthesis of potent water-soluble tissue transglutaminase inhibitors

  摘要：

  Dipeptide-based sulfonium peptidylmethylketones derived from 6-diazo-5-oxo-L-norleucine (DON) have been investigated as potential water-soluble inhibitors of extracellular transglutaminase. The lead compounds were prepared in four steps and exhibited potent activity against tissue transglutaminase. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.006
• 作为产物：
  描述：

  在 氢溴酸 、 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 生成 Boc-Phe-Glu(CH2Br)(CH2Br)-OH
  参考文献：
  名称：

  Synthesis of potent water-soluble tissue transglutaminase inhibitors

  摘要：

  Dipeptide-based sulfonium peptidylmethylketones derived from 6-diazo-5-oxo-L-norleucine (DON) have been investigated as potential water-soluble inhibitors of extracellular transglutaminase. The lead compounds were prepared in four steps and exhibited potent activity against tissue transglutaminase. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.006

文献信息

• DIPEPTIDE TRANSGLUTAMINASE INHIBITORS AND METHODS OF USING THE SAME
  申请人：Aston University

  公开号：EP1648924B1

  公开（公告）日：2008-07-30
• Novel Compounds and Methods of Using the Same
  申请人：Griffin Martin

  公开号：US20080200511A1

  公开（公告）日：2008-08-21

  The present invention relates to novel compounds of Formula (I) wherein ‘X’ represents an amino acid group, ‘n’ is an integer between 1 and 4, ‘R 1 ’ represents benzyl, t-butyl or 9-fluorenylmethyl and ‘R 2 ’ represents a tetramethylmercaptoimidazole derivative or —S + R 3 R 4 , wherein R 3 and R 4 each independently represent lower alkyl, or a pharmaceutically and/or veterinarily acceptable derivative thereof. The present invention further relates to pharmaceutical formulations of said compound and the use thereof in the preparation of a medicament for inhibiting diseases in which transglutaminase has been implicated. Advantageously, the medicament is for treating fibrosis, scarring and/or cancer. Additionally, the invention relates to a method of inhibiting autoimmune diseases such as coeliac disease, neurodegeneration and chronic inflammatory diseases (e.g. of the joints including rheumatoid arthritis and osteoarthritis in a subject). The invention further relates to a method for preventing or treating rejection of a transplanted organ.
• US7723307B2
  申请人：——

  公开号：US7723307B2

  公开（公告）日：2010-05-25